% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Rusthoven:275797,
      author       = {C. G. Rusthoven and A. W. Staley and D. Gao and S. Yomo and
                      D. Bernhardt and N. Wandrey and R. El Shafie and A. Kraemer
                      and O. Padilla and V. Chiang and A. M. Faramand and J. D.
                      Palmer and B. E. Zacharia and R. E. Wegner and J. A.
                      Hattangadi-Gluth and A. Levy and K. Bernstein and D. Mathieu
                      and D. N. Cagney and M. D. Chan and I. S. Grills and S.
                      Braunstein and C.-C. Lee and J. P. Sheehan and C. Kluwe and
                      S. Patel and L. M. Halasz and N. Andratschke and C. P.
                      Deibert and V. Verma and D. M. Trifiletti and C. P.
                      Cifarelli and J. Debus$^*$ and S. E. Combs and Y. Sato and
                      Y. Higuchi and K. Aoyagi and P. D. Brown and V. Alami and A.
                      Niranjan and L. D. Lunsford and D. Kondziolka and D. R.
                      Camidge and B. D. Kavanagh and T. P. Robin and T. Serizawa
                      and M. Yamamoto},
      title        = {{C}omparison of {F}irst-{L}ine {R}adiosurgery for
                      {S}mall-{C}ell and {N}on-{S}mall {C}ell {L}ung {C}ancer
                      {B}rain {M}etastases ({C}ross-{FIRE}).},
      journal      = {Journal of the National Cancer Institute},
      volume       = {115},
      number       = {8},
      issn         = {0027-8874},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2023-00885},
      pages        = {926-936},
      year         = {2023},
      note         = {2023 Aug 8;115(8):926-936},
      abstract     = {Historical reservations regarding radiosurgery (SRS) for
                      small-cell-lung-cancer (SCLC) brain metastases (BrM) include
                      concerns for short-interval/diffuse CNS-progression, poor
                      prognoses, and increased neurological mortality specific to
                      SCLC histology. We compared SRS outcomes for SCLC and
                      non-small-cell-lung-cancer (NSCLC) where SRS is well
                      established.Multicenter first-line SRS outcomes for SCLC and
                      NSCLC from 2000-2022 were retrospectively collected
                      (N=892-SCLC/N=4,785-NSCLC). Data from the prospective
                      JLGK0901 SRS trial were analyzed as a comparison cohort
                      (N=98-SCLC/N=794-NSCLC). OS and CNS-progression were
                      analyzed using Cox-Proportional-Hazard and Fine-Gray models,
                      respectively, with multivariable (MV) adjustment (including
                      age/sex/performance-status/year/extracranial
                      disease/BrM-number/BrM-volume). Mutation-stratified analyses
                      were performed in propensity score-matched (PSM)
                      retrospective cohorts of EGFR/ALK-positive-NSCLC,
                      mutation-negative-NSCLC, and SCLC.OS was superior with NSCLC
                      over SCLC in the retrospective dataset (median-OS, 10.5 vs
                      8.6 months, MV-p<0.001) and JLGK0901. Hazard estimates for
                      first CNS-progression favoring NSCLC were similar in both
                      datasets but reached significance in the retrospective
                      dataset only (MV-HR:0.82 $[95\%-CI:0.73-0.92],$ p=0.001). In
                      the PSM cohorts, there were continued OS advantages for
                      NSCLC (median-OS, 23.7 [EGFR/ALK-positive-NSCLC] vs 13.6
                      [mutation-negative-NSCLC] vs 10.4 months [SCLC],
                      pairwise-p-values<0.001), but no significant differences in
                      CNS-progression. Neurological mortality and number of
                      lesions at CNS-progression were similar for NSCLC and SCLC
                      patients. Leptomeningeal-progression was increased in NSCLC
                      patients in the retrospective dataset only (MV-HR:1.61
                      $[95\%-CI:1.14-2.26],$ p=0.007).After SRS, SCLC was
                      associated with shorter OS compared to NSCLC. CNS
                      progression occurred earlier in SCLC overall but was similar
                      in patients matched on baseline characteristics.
                      Neurological mortality, lesions at CNS-progression, and
                      leptomeningeal-progression were comparable. These findings
                      may better inform clinical decision-making for SCLC
                      patients.},
      keywords     = {brain metastases (Other) / non-small cell lung cancer
                      (NSCLC) (Other) / small-cell lung cancer (SCLC) (Other) /
                      stereotactic radiosurgery (SRS) (Other) / whole brain
                      radiation therapy (WBRT) (Other)},
      cin          = {HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)HD01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37142267},
      doi          = {10.1093/jnci/djad073},
      url          = {https://inrepo02.dkfz.de/record/275797},
}